BR112019028046A2 - métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos - Google Patents

métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos Download PDF

Info

Publication number
BR112019028046A2
BR112019028046A2 BR112019028046-4A BR112019028046A BR112019028046A2 BR 112019028046 A2 BR112019028046 A2 BR 112019028046A2 BR 112019028046 A BR112019028046 A BR 112019028046A BR 112019028046 A2 BR112019028046 A2 BR 112019028046A2
Authority
BR
Brazil
Prior art keywords
subject
dose
asc
initial
fact
Prior art date
Application number
BR112019028046-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Narimon Honarpour
Malik Fady
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of BR112019028046A2 publication Critical patent/BR112019028046A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112019028046-4A 2017-06-30 2018-06-29 métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos BR112019028046A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
BR112019028046A2 true BR112019028046A2 (pt) 2020-07-07

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019028046-4A BR112019028046A2 (pt) 2017-06-30 2018-06-29 métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos

Country Status (22)

Country Link
US (4) US11576910B2 (enExample)
EP (2) EP4512470A3 (enExample)
JP (3) JP2020526483A (enExample)
CN (1) CN110996953A (enExample)
AU (2) AU2018290983B2 (enExample)
BR (1) BR112019028046A2 (enExample)
CA (1) CA3068588A1 (enExample)
DK (1) DK3645002T3 (enExample)
ES (1) ES3008457T3 (enExample)
FI (1) FI3645002T3 (enExample)
HR (1) HRP20241729T1 (enExample)
HU (1) HUE069805T2 (enExample)
LT (1) LT3645002T (enExample)
MA (1) MA49508B1 (enExample)
MD (1) MD3645002T2 (enExample)
MX (2) MX2020000190A (enExample)
PL (1) PL3645002T3 (enExample)
PT (1) PT3645002T (enExample)
RS (1) RS66581B1 (enExample)
SI (1) SI3645002T1 (enExample)
SM (1) SMT202500067T1 (enExample)
WO (1) WO2019006235A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151786A1 (es) 2013-03-14 2015-12-11 Amgen Inc Compuestos heterociclicos y sus usos
SG10202111790YA (en) 2017-06-30 2021-12-30 Amgen Inc Synthesis of omecamtiv mecarbil
MA49508B1 (fr) * 2017-06-30 2024-12-31 Amgen Inc. Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
BR112021023074A2 (pt) * 2019-05-19 2022-03-29 Myokardia Inc Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida
JP7696353B2 (ja) * 2020-02-10 2025-06-20 アムジェン インコーポレイテッド オメカムチブメカルビル製剤
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
EP4243825B1 (en) 2020-11-12 2025-11-12 Amgen Inc. Omecamtiv mecarbil for the treatment of heart failure in selected patient groups
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
CN1296417A (zh) 1998-02-10 2001-05-23 卫福有限公司 控释制剂
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
AU2014240104B2 (en) * 2013-03-14 2018-11-08 Amgen Inc. Heterocyclic compounds and their uses
PE20151786A1 (es) 2013-03-14 2015-12-11 Amgen Inc Compuestos heterociclicos y sus usos
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX379899B (es) * 2015-06-26 2025-03-11 Cytokinetics Inc Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal
AU2018214629A1 (en) 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
MA49508B1 (fr) 2017-06-30 2024-12-31 Amgen Inc. Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
SG10202111790YA (en) 2017-06-30 2021-12-30 Amgen Inc Synthesis of omecamtiv mecarbil
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
PL3599243T3 (pl) 2018-07-26 2023-08-21 Cvie Therapeutics Limited Związki podobne do 17beta-heterocyklilu naparstnicy do leczenia niewydolności serca
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
BR112021017009A2 (pt) 2019-03-05 2021-11-09 Windtree Therapeutics Inc Formulação intravenosa contendo istaroxima para o tratamento da insuficiência cardíaca aguda (ahf)
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (en) 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
AU2020378197A1 (en) 2019-11-10 2022-05-26 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
JP7696353B2 (ja) 2020-02-10 2025-06-20 アムジェン インコーポレイテッド オメカムチブメカルビル製剤
EP4243825B1 (en) 2020-11-12 2025-11-12 Amgen Inc. Omecamtiv mecarbil for the treatment of heart failure in selected patient groups
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
DK3645002T3 (da) 2024-12-16
US20250255862A1 (en) 2025-08-14
AU2018290983A1 (en) 2020-01-23
ES3008457T3 (en) 2025-03-24
MX2022015115A (es) 2023-01-18
MD3645002T2 (ro) 2025-04-30
AU2024200991A1 (en) 2024-03-07
MX2020000190A (es) 2020-07-22
JP2020526483A (ja) 2020-08-31
FI3645002T3 (fi) 2025-01-29
MA49508A (fr) 2020-05-06
HRP20241729T1 (hr) 2025-03-14
HUE069805T2 (hu) 2025-04-28
JP2025165979A (ja) 2025-11-05
US12295952B2 (en) 2025-05-13
JP2023088944A (ja) 2023-06-27
AU2018290983B2 (en) 2023-11-23
MA49508B1 (fr) 2024-12-31
SI3645002T1 (sl) 2025-03-31
CN110996953A (zh) 2020-04-10
PT3645002T (pt) 2025-01-24
US11576910B2 (en) 2023-02-14
WO2019006235A1 (en) 2019-01-03
SMT202500067T1 (it) 2025-03-12
EP4512470A3 (en) 2025-04-23
AU2024200991B2 (en) 2025-04-10
US20230149394A1 (en) 2023-05-18
CA3068588A1 (en) 2019-01-03
US11931358B2 (en) 2024-03-19
EP3645002A1 (en) 2020-05-06
US20200155547A1 (en) 2020-05-21
LT3645002T (lt) 2025-02-10
EP4512470A2 (en) 2025-02-26
RS66581B1 (sr) 2025-04-30
PL3645002T3 (pl) 2025-03-24
EP3645002B1 (en) 2024-10-30
US20230355615A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
US11931358B2 (en) Methods of treating heart failure with cardiac sarcomere activators
Sayin et al. Left ventricular hypertrophy: etiology-based therapeutic options
US20220313695A1 (en) Treatment of hcm with pyrimidinedione compounds
Upadhya et al. Heart failure with preserved ejection fraction in older adults
Cohn Current therapy of the failing heart.
ES3014965T3 (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024500616A (ja) オメカムチブメカルビルの投与により心不全を処置する方法
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
Kobayashi et al. A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design
WO2018189671A1 (en) Use of lik066 in heart failure patients
Woodland et al. New Era: Mavacamten for obstructive hypertrophic cardiomyopathy
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
AU2018343239A1 (en) Dosing regimen of siponimod
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40027649A (en) Methods of treating heart failure with cardiac sarcomere activators
Buitenwerf et al. Efficacy of phenoxybenzamine versus doxazosin on hemodynamic control during pheochromocytoma resection-a randomized controlled trial. Supplemental data. Figshare repository
Finimundi et al. Effect of diuretic therapy on exercise capacity in patients with chronic angina and preserved left ventricular function
Hamze et al. Sodium-glucose cotransporter 2 inhibition restores testicular microvascular perfusion via endothelial signaling in a large animal model of metabolic syndrome and heart failure
Oto Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Johnson Management of patients with left ventricular hypertrophy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]